These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 19267736

  • 1. Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer.
    Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, Turhal NS.
    Eur J Cancer Care (Engl); 2009 Mar; 18(2):191-4. PubMed ID: 19267736
    [Abstract] [Full Text] [Related]

  • 2. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer.
    Beckers MM, Ruven HJ, Seldenrijk CA, Prins MH, Biesma DH.
    Thromb Res; 2010 Apr; 125(4):318-21. PubMed ID: 19640573
    [Abstract] [Full Text] [Related]

  • 3. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
    Mismetti P, Mille D, Laporte S, Charlet V, Buchmüller-Cordier A, Jacquin JP, Fournel P, Dutrey-Dupagne C, Decousus H, CIP Study Group.
    Haematologica; 2003 Jan; 88(1):67-73. PubMed ID: 12551829
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2.
    Eastman ME, Khorsand M, Maki DG, Williams EC, Kim K, Sondel PM, Schiller JH, Albertini MR.
    Cancer; 2001 Feb 15; 91(4):806-14. PubMed ID: 11241250
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Role of totally implantable systems for long-term vascular access in the treatment of the neoplastic patient].
    Aldrighetti L, Caterini R, Ronzoni M, Jannello A, Ferla G.
    Minerva Chir; 1995 May 15; 50(5):447-54. PubMed ID: 7478055
    [Abstract] [Full Text] [Related]

  • 11. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer.
    Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA.
    J Clin Oncol; 2006 Mar 20; 24(9):1404-8. PubMed ID: 16549834
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for catheter-related thrombosis in cancer patients.
    Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S.
    Eur J Cancer; 2004 Oct 20; 40(15):2253-9. PubMed ID: 15454250
    [Abstract] [Full Text] [Related]

  • 13. Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter.
    Vlasveld LT, Rodenhuis S, Rutgers EJ, Dubbelman AC, Hilton AM, Batchelor D, Rankin EM.
    Eur J Surg Oncol; 1994 Apr 20; 20(2):122-9. PubMed ID: 8181576
    [Abstract] [Full Text] [Related]

  • 14. Risk factors for early catheter-related infections in cancer patients.
    Penel N, Neu JC, Clisant S, Hoppe H, Devos P, Yazdanpanah Y.
    Cancer; 2007 Oct 01; 110(7):1586-92. PubMed ID: 17685401
    [Abstract] [Full Text] [Related]

  • 15. [Safety and effectiveness of central vein catheters indwelling with subcutaneous port in patients undergoing chemotherapy].
    Ge F, Cang J, Xue ZG.
    Zhonghua Yi Xue Za Zhi; 2008 Aug 26; 88(33):2331-4. PubMed ID: 19087693
    [Abstract] [Full Text] [Related]

  • 16. Does low-dose heparin maintain central venous access device patency?: a comparison of heparin versus saline during a period of heparin shortage.
    Jonker MA, Osterby KR, Vermeulen LC, Kleppin SM, Kudsk KA.
    JPEN J Parenter Enteral Nutr; 2010 Aug 26; 34(4):444-9. PubMed ID: 20631392
    [Abstract] [Full Text] [Related]

  • 17. Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients.
    Piran S, Ngo V, McDiarmid S, Le Gal G, Petrcich W, Carrier M.
    Thromb Res; 2014 Jan 26; 133(1):30-3. PubMed ID: 24188799
    [Abstract] [Full Text] [Related]

  • 18. Concentration of heparin-locking solution and risk of central venous hemodialysis catheter malfunction.
    Thomas CM, Zhang J, Lim TH, Scott-Douglas N, Hons RB, Hemmelgarn BR, Alberta Kidney Disease Network.
    ASAIO J; 2007 Jan 26; 53(4):485-8. PubMed ID: 17667236
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneously implanted central venous access device infection in pediatric patients with cancer.
    Hung MC, Chen CJ, Wu KG, Hung GY, Lin YJ, Tang RB.
    J Microbiol Immunol Infect; 2009 Apr 26; 42(2):166-71. PubMed ID: 19597650
    [Abstract] [Full Text] [Related]

  • 20. [Long-term outcomes and complications of upper arm central venous access ports].
    Ide Y, Mikami K, Murata K.
    Gan To Kagaku Ryoho; 2013 Mar 26; 40(3):331-5. PubMed ID: 23507594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.